Literature DB >> 18452695

Genetic predisposition for monoclonal gammopathy of undetermined significance.

Guillermo J Ruiz-Delgado, Guillermo J Ruiz-Argüelles.   

Abstract

Mesh:

Year:  2008        PMID: 18452695     DOI: 10.4065/83.5.601-a

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  6 in total

1.  On the prevalence and genetic predisposition of monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Guillermo J Ruiz-Argüelles; Guillermo J Ruiz-Delgado
Journal:  Int J Hematol       Date:  2012-06-03       Impact factor: 2.490

Review 2.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

Review 3.  From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.

Authors:  Ola Landgren; Robert A Kyle; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2011-03-15       Impact factor: 12.531

Review 4.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

5.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

Authors:  Celine M Vachon; Robert A Kyle; Terry M Therneau; Barbara J Foreman; Dirk R Larson; Colin L Colby; Tara K Phelps; Angela Dispenzieri; Shaji K Kumar; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 6.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.